About this item:

268 Views | 117 Downloads

Author Notes:

Correspondence to: Joshua M. Levy, MD, MPH, Department of Otolaryngology–Head and Neck Surgery, Emory University School of Medicine, 550 Peachtree Street NE, Medical Office Tower, Suite 1135, Atlanta, GA 30308; Joshua.Levy2@emory.edu.

The authors are grateful for the training and sample preparation provided by the CF@LANTA RDP Experimental Models Support Core of the Emory University School of Medicine.

J.D.: IntersectENT (Menlo Park, CA), stockholder; and Spirox (Redwood City, CA), research support.

S.W.: Medtronic (Minneapolis, MN), consultant; and Elron (Tel Aviv, Israel), consultant; OptiNose (Yardley, PA), scientific advisory board; SynopSys Surgical (Boulder, CO), scientific advisory board.

F.E.H.L.: MicroB-plex, Inc., company founder.

Subject:

Research Funding:

Immunohistochemistry was provided by Winship Research Pathology Core of Emory University School of Medicine.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Otorhinolaryngology
  • sinusitis
  • chronic disease
  • aspirin-induced asthma
  • endocannabinoid
  • CHRONIC RHINOSINUSITIS
  • NASAL POLYPOSIS
  • CELLS

Endocannabinoid receptor CB2R is significantly expressed in aspirin-exacerbated respiratory disease: a pilot study

Tools:

Journal Title:

International Forum of Allergy and Rhinology

Volume:

Volume 8, Number 10

Publisher:

, Pages 1184-1189

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: The endocannabinoid system represents a highly conserved, innate signaling network with direct and indirect control of eicosanoid-mediated inflammation. Activation of the type 2 cannabinoid receptor (CB2R) leads to decreased type 2 inflammation and reduced production of arachidonic acid (AA). Given that altered AA metabolism is associated with aspirin-exacerbated respiratory disease (AERD), we hypothesized that expression of the CB2R gene CNR2 is increased in AERD. Methods: Nasal polyps from consecutive patients undergoing endoscopic sinus surgery for AERD or allergic fungal rhinosinusitis (AFRS) were prospectively evaluated. Control sphenoid mucosa was collected from patients undergoing endoscopic skull base procedures. Expression and localization of endocannabinoid receptors were evaluated by quantitative reverse transcript–polymerase chain reaction (qRT-PCR) and immunohistochemistry. A 2-group unpaired t test with unequal variances was used to evaluate group differences. Results: Thirteen subjects were included in this pilot study, including 5 controls, 5 AFRS patients, and 3 AERD patients. Upregulated expression of CNR2 was detected in subjects with AERD vs both AFRS (p = 0.049) and controls (p = 0.047), with a mean increase of 5.2-fold. No significant differences in expression of the CB1R gene CNR1 were detected between control and AFRS groups. Immunohistochemistry predominantly localized CB1R and CB2R expression to the surface epithelium in all subjects. Conclusion: The endocannabinoid system is an emerging immunomodulatory network that may be involved in AERD. This is the first study of CB2R in sinonasal disease, showing significantly increased transcription in nasal polyps from subjects with AERD. Additional study is warranted to further evaluate the contribution and therapeutic potential of this novel finding in chronic rhinosinusitis.

Copyright information:

© 2018 ARS-AAOA, LLC

Export to EndNote